1. Home
  2. SWBI vs DSGN Comparison

SWBI vs DSGN Comparison

Compare SWBI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith & Wesson Brands Inc.

SWBI

Smith & Wesson Brands Inc.

HOLD

Current Price

$11.65

Market Cap

491.2M

Sector

Industrials

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

SELL

Current Price

$10.26

Market Cap

579.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SWBI
DSGN
Founded
1852
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Ordnance And Accessories
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
491.2M
579.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SWBI
DSGN
Price
$11.65
$10.26
Analyst Decision
Strong Buy
Buy
Analyst Count
1
3
Target Price
$11.00
$15.00
AVG Volume (30 Days)
559.1K
298.1K
Earning Date
03-05-2026
03-09-2026
Dividend Yield
4.45%
N/A
EPS Growth
N/A
N/A
EPS
0.21
N/A
Revenue
$466,396,000.00
N/A
Revenue This Year
$2.62
N/A
Revenue Next Year
$3.23
N/A
P/E Ratio
$55.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.73
$2.60
52 Week High
$12.05
$10.97

Technical Indicators

Market Signals
Indicator
SWBI
DSGN
Relative Strength Index (RSI) 66.57 54.22
Support Level $11.33 $9.54
Resistance Level $12.05 $10.75
Average True Range (ATR) 0.39 0.69
MACD 0.05 -0.04
Stochastic Oscillator 70.47 59.69

Price Performance

Historical Comparison
SWBI
DSGN

About SWBI Smith & Wesson Brands Inc.

Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: